BTAI · BioXcel Therapeutics, Inc.
Substantial doubt about the company's ability to continue as a going concern.
“We have identified conditions and events that raise substantial doubt about our ability to continue as a going concern.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| $742K | $642K | $2.27M | $1.38M | $375K | — | — | — | — | — | |
| $348K | $164K | $2.14M | $1.26M | $20K | — | — | — | — | — | |
| $394K | $478K | $123K | $120K | $355K | — | — | — | — | — | |
| — | 74.45% | 5.43% | 8.7% | 94.67% | — | — | — | — | — | |
| $21.56M | $30.25M | $30.44M | $84.33M | $91.24M | $52.71M | $58M | $25.8M | $14.56M | $2.69M | |
| $55.51M | — | — | — | — | $54.23M | $24.3M | $7.8M | $5.4M | $1.85M | |
| $23.57M | $20.49M | $34.49M | $83.41M | $68.76M | $54.23M | — | — | — | — | |
| $309K | — | — | — | — | $297K | $188K | $156K | $17K | $1000 | |
| $0 | $194K | $2.44M | $4.16M | — | — | — | — | — | — | |
| $120.71M | — | — | — | — | $106.94M | $82.3M | $33.6M | $19.96M | $4.54M | |
| $45.67M | $51.1M | $69.51M | $173.16M | $160.02M | $106.94M | — | — | — | — | |
| -$44.93M | -$50.46M | -$67.25M | -$171.78M | -$159.65M | -$106.94M | -$82.3M | -$33.6M | -$19.96M | -$4.54M | |
| — | -7859.97% | -2967.56% | -12447.97% | -42572% | — | — | — | — | — | |
| -$111.73M | — | — | — | — | -$106.64M | -$82.11M | -$33.45M | -$19.95M | -$4.54M | |
| $17.22M | $16.98M | $15.13M | $13.31M | $8.21M | $40K | $27K | $20K | — | — | |
| $899K | $1.07M | $2.6M | $5.65M | $2.53M | $44K | $155K | — | — | — | |
| -$9.61M | -$3.52M | $20.17M | $394K | -$427K | — | — | — | — | — | |
| — | $0 | $0 | $0 | — | — | — | — | — | — | |
| -$70.86M | -$69.9M | -$59.6M | -$179.05M | -$165.76M | -$106.93M | -$82.17M | -$32.97M | -$19.27M | -$4.54M | |
| — | -10887.38% | -2630.14% | -12974.86% | -44201.87% | — | — | — | — | — | |
| USD/shares | -$2.81 | -$5.73 | -$23.51 | -$98.33 | -$94.72 | -$64.80 | -$60.64 | — | — | — |
| USD/shares | -$2.81 | -$5.73 | -$23.51 | -$98.33 | -$94.72 | -$64.80 | -$60.64 | — | — | — |
| shares | — | 12.21M | 2.54M | 1.82M | 1.75M | 1.65M | 1.36M | 1.02M | 910.72K | 605.31K |
| shares | — | 12.21M | 2.54M | 1.82M | 1.75M | 1.65M | 1.36M | 1.02M | 910.72K | 605.31K |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 26 similar-size Drug Manufacturers - Specialty & Generic companies (of 94 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Single Reportable Segment | $642,000 | $2,266,000 | $1,380,000 |